The subcutaneous formulation of the bispecific antibody reduces treatment time to 1 minute vs 2-4 hours with IV infusion. Medscape Medical News Source link : https://www.medscape.com/viewarticle/fda-oks-subcutaneous-mosunetuzumab-follicular-lymphoma-2025a1001093?src=rss Author : Publish date...
Read more
















